Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof
A crystal form A of a 3,4-dihydrothieno[3,2-d]pyrimidine compound (1), a preparation method therefor and an application thereof in the preparation of an anti-human cytomegalovirus (HCMV) drug.
1. A crystal form A of compound 1, wherein the X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 17.69±0.2°, 20.00±0.2°, and 20.63±0.2°,
2. The crystal form A of compound 1 according to claim 1 , wherein the X-ray powder diffraction pattern thereof has characteristic diffraction peaks at the following 2θ angles: 9.15±0.2°, 11.06±0.2°, 11.95±0.2°, 17.69±0.2°, 19.03±0.2°, 19.46±0.2°, 20.00±0.2°, and 20.63±0.2°.
3. The crystal form A of compound 1 according to claim 2 , wherein the XRPD pattern thereof is shown in FIG. 1 .
4. The crystal form A of compound 1 according to claim 1 wherein the differential scanning calorimetry curve thereof has a starting point of the endothermic peak at 214.47±° C.
5. The crystal form A of compound 1 according to claim 4 , wherein the DSC curve thereof is shown in FIG. 2 .
6. The crystal form A of compound 1 according to claim 1 wherein the thermogravimetric analysis curve thereof has a weight loss of 0.1206% at 120.00±2° C.
7. The crystal form A of compound 1 according to claim 6 , wherein the TGA curve thereof is shown in FIG. 3 .
8. A method of preparing the crystal form A of compound 1,
comprising adding the compound 1 to a mixed solvent of alcoholic solvent and water, heating to dissolve, and then cooling and crystallizing.
9. The method of preparing the crystal form A of compound 1 according to claim 8 , wherein the alcoholic solvent is selected from the group consisting of methanol, ethanol and isopropanol.
10. The method of preparing the crystal form A of compound 1 according to claim 8 , wherein the mixed solvent of alcoholic solvent and water is a mixed solvent of ethanol and water.
11. The method of preparing the crystal form A of compound 1 according to claim 8 , wherein in the mixed solvent of alcoholic solvent and water, the volume ratio of the alcoholic solvent to water is selected from 1:0.2 to 1:1.5.
12. A method of treating a disease related to HCMV virus in a subject in need thereof, comprising administering to the subject the crystal form A of compound 1 according to claim 1 .
13. The crystal form A of compound 1 according to claim 4 , wherein the thermogravimetric analysis curve thereof has a weight loss of 0.1206% at 120.00±2° C.
14. The crystal form A of compound 1 according to claim 7 , wherein the TGA curve thereof is shown in FIG. 3 .